The stock of Novocure Ltd (NASDAQ:NVCR) is a huge mover today! The stock decreased 1.38% or $0.1 during the last trading session, hitting $7.15. About 346,831 shares traded hands or 21.03% up from the average. Novocure Ltd (NASDAQ:NVCR) has declined 48.80% since April 6, 2016 and is downtrending. It has underperformed by 50.76% the S&P500.
The move comes after 9 months negative chart setup for the $676.46M company. It was reported on Nov, 8 by Barchart.com. We have $6.51 PT which if reached, will make NASDAQ:NVCR worth $60.88M less.
Novocure Ltd (NASDAQ:NVCR) Ratings Coverage
Out of 5 analysts covering NovoCure (NASDAQ:NVCR), 3 rate it a “Buy”, 1 “Sell”, while 1 “Hold”. This means 60% are positive. NovoCure has been the topic of 6 analyst reports since October 27, 2015 according to StockzIntelligence Inc. JMP Securities initiated the stock with “Market Outperform” rating in Tuesday, October 27 report. Wedbush maintained the stock with “Outperform” rating in Friday, July 29 report. The firm earned “Hold” rating on Wednesday, December 2 by Deutsche Bank. JP Morgan initiated the shares of NVCR in a report on Tuesday, October 27 with “Overweight” rating. On Tuesday, October 27 the stock rating was initiated by Wedbush with “Outperform”. The stock has “Underweight” rating given by Barclays Capital on Tuesday, January 19.
According to Zacks Investment Research, “NovoCure Limited is an oncology company. The Company is engaged in developing a therapy called Tumor Treating Fields for the treatment of solid tumor cancers. It operates primarily in the United States, Germany, Switzerland and Japan. NovoCure Limited is based in Saint Helier, Channel Islands.”
More important recent Novocure Ltd (NASDAQ:NVCR) news were published by: Marketwatch.com which released: “Novocure Ltd. NASDAQ: NVCR” on September 02, 2015, also Fool.com published article titled: “Why Novocure Ltd Is Plunging Today”, Quotes.Wsj.com published: “Novocure Ltd. NVCR (US: Nasdaq)” on September 02, 2015. More interesting news about Novocure Ltd (NASDAQ:NVCR) was released by: Marketwatch.com and their article: “NovoCure falls below reduced IPO price in market debut” with publication date: October 02, 2015.
NVCR Company Profile
NovoCure Limited, incorporated on February 11, 2000, is a commercial-stage oncology company. The Firm is engaged in developing a therapy called TTFields for the treatment of solid tumor cancers. TTFields is a low-toxicity anti-mitotic treatment that uses low-intensity, intermediate frequency, alternating electric fields to exert physical forces on molecules inside cancer cells, disrupting the basic machinery for normal cell division, leading to cancer cell death. A TTFields delivery system includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories. The electric fields are delivered through the non-invasive, insulated transducer arrays that are placed directly on the skin in the region surrounding the tumor. The therapy is designed to be delivered throughout the day and night.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.